Breakthrough in the production of dopamine neurons for Parkinson's disease

October 28, 2016
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

The first transplantation of stem cells in patients with Parkinson's disease is almost within reach. However, it remains a challenge for researchers to control stem cells accurately in the lab in order to achieve successful and functional stem cell therapies for patients.

"In our preclinical assessments of stem cell-derived dopamine neurons we noticed that the outcome in animal models varied dramatically, even though the cells were very similar at the time of transplantation. This has been frustrating and puzzling, and has significantly delayed the establishment of clinical cell production protocols," says Malin Parmar, who led the study conducted at Lund University as part of the EU network NeuroStemcellRepair.

The Lund experiments use modern global gene expression studies to better understand the path from a stem cell to a dopamine neuron. The data has been generated in close collaboration with a team of scientists at Karolinska Institute lead by Professor Thomas Perlmann, and is closely linked with a second study from the same cluster of scientists. The second study sheds new light on how dopamine neurons are formed during development, and what makes them different from other similar and neighbouring neurons.

This new insight has enabled a streamlined differentiation process resulting in pure populations of of high quality.

"We have identified a specific set of markers that correlate with high dopaminergic yield and graft function after transplantation in animal models of Parkinson's disease. Guided by this information, we have developed a better and more accurate methods for producing dopamine cells for clinical use in a reproducible way," says first author Agnete Kirkeby.

The new results, published in two back-to-back articles in the leading journal in the field, Cell Stem Cell, propel for Parkinson's disease towards clinical application. The first transplants are expected to be only a few years away.

Explore further: Midbrain study gives boost to Parkinson's research

More information: Agnete Kirkeby et al. Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease, Cell Stem Cell (2016). DOI: 10.1016/j.stem.2016.09.004

Nigel Kee et al. Single-Cell Analysis Reveals a Close Relationship between Differentiating Dopamine and Subthalamic Nucleus Neuronal Lineages, Cell Stem Cell (2016). DOI: 10.1016/j.stem.2016.10.003

Related Stories

Midbrain study gives boost to Parkinson's research

October 10, 2016

Two research teams at Karolinska Institutet have identified the dopamine-producing cells in the midbrain of mice and humans. They have also developed a method of assessing the quality of in-vitro cultured dopamine-producing ...

Generating dopamine via cell therapy for Parkinson's disease

July 2, 2012

In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's ...

From stem cell to brain cell - new technique mimics the brain

May 24, 2012

A new technique that converts stem cells into brain cells has been developed by researchers at Lund University. The method is simpler, quicker and safer than previous research has shown and opens the doors to a shorter route ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.